Form 4: Replimune Group Director Weinand Acquires Stock Options
SEC Form 4 Filing
Director Dieter Weinand of Replimune Group, Inc. reports acquisition of stock options.
Summary
- Dieter Weinand, a director of Replimune Group, Inc., filed a Form 4.
- The form reports a transaction that occurred on April 1, 2025.
- Weinand acquired 32,000 stock options with an exercise price of $8.40.
- The options vest entirely on April 1, 2026, and expire on April 1, 2035.
- Following the transaction, Weinand directly owns 32,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of executive compensation packages.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of transaction: Acquisition of stock options. |
| 04/01/2026 | Vesting date for the stock options. |
| 04/01/2035 | Expiration date for the stock options. |
| 04/03/2025 | Date of Form 4 filing. |
Keywords
Form 4, Replimune Group, Stock Options, Director, Weinand, Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.